VERA
Vera TherapeuticsCOperating peers and competitors
Source-backed product markets and frozen research comparisons. Valuation comparators remain in the existing peer table.
Loading market evidence...
Research comparisons do not establish forecast usefulness or trading returns.
Compare shared product markets
Membership only; no portfolio weights or estimated losses.
Peer overview
Direct IgAN commercial comparator through FILSPARI, although its product and portfolio differ from Vera's. Travere reported second-quarter 2026 FILSPARI net sales of $141.1 million; this illustrates an established market, not a forecast for TRUTAKNA. [Travere Q2 release](https://ir.travere.com/press-releases/news-details/2026/Travere-Therapeutics-Reports-Second-Quarter-2026-Financial-Results/default.aspx)
Grade position vs TVTX
Rotation landscape
Peers ranked by the order returned from the peer source, with grades from the API.

